Vesalius Announces Multi-Target Strategic Alliance with GSK to …
2 days ago · Vesalius will leverage its platform to identify novel intervention points in Parkinson's disease and one additional indication in neurodegeneration, and GSK will have the option to advance ...
Vesalius Announces Multi-Target Strategic Alliance with GSK
2 days ago · Vesalius Will Apply its Proprietary Platform to Identify Novel Intervention Points that GSK may Advance for the Treatment of Patients with Parkinson’s Disease GSK has Licensed a Preclinical Small Molecule Inhibitor Program CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Vesalius Therapeutics, a ...
GSK pays Flagship biotech $80M for preclinical neuro pact
2 days ago · GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks. GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Vesalius Announces Multi-Target Strategic Alliance with GSK to …
2 days ago · Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic alliance with GSK to discover ...
GSK Steps Up Parkinson’s Focus With US Biotech Deal
2 days ago · GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease.. GSK will pay $80 million ...
GSK partners with Flagship startup to hunt for Parkinson’s drugs
3 days ago · Permission granted by Flagship Pioneering. Flagship Pioneering startup Vesalius Therapeutics has signed a deal with GSK, the companies announced Tuesday, for the British pharma to use its technology to find medicines for neurodegenerative disorders. Under the terms of the deal, GSK will hand Vesalius $80 million in upfront and equity payments.
Vesalius Announces Multi-Target Strategic… | Flagship Pioneering
3 days ago · Cambridge, Mass., November 12, 2024 – Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic alliance with GSK to discover and develop novel treatments for Parkinson’s disease, and another undisclosed neurodegenerative indication.
Vesalius-GSK $650M pact: Targeting Parkinson’s root causes
2 days ago · More than two years since emerging from stealth, Vesalius Therapeutics Inc. signed its first major pharma deal with GSK plc. Worth up to $650 million and possibly more if an option is exercised, the multitarget alliance aims to discover and develop novel treatments for Parkinson’s disease and another neurodegenerative indication. Nearly $3.8 ...
GSK inks multi-target alliance with Versalius | Biotechnology | The ...
1 day ago · 13 November 2024. Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK (LSE: GSK) to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. The deal marks GSK's second major foray into neurodegenerative diseases in recent ...
Vesalius Announces Multi-Target Strategic Alliance with GSK to …
2 days ago · Under the terms of the agreement, GSK will be responsible for advancing Vesalius' preclinical small molecule program with an initial focus in Parkinson's disease and has the option to advance ...
- Some results have been removed